Medical & Biotech


EMA official suggests ditching AstraZeneca jab

A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca's coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday. Marco Cavaleri, the EMA's head of vaccine strategy, also told Italy's La Stampa newspaper that the Johnson & Johnson jab...
Picture for EMA official suggests ditching AstraZeneca jab
IndustryPosted by

The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs

Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in the form of approval for Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's drug Aduhelm. The approval polarized the scientific community. The stock, which at one point tacked on about 64% on the day of the approval, ended the week up about 40%.

Breakthrough in Understanding How Effective Tissue Regeneration Works

A researcher has discovered an alternative signaling pathway that is compatible with regeneration of tissues. This could ultimately lead to regenerative medicine therapies for humans. This could help us to create therapies that improve clinical outcomes in diseases in which scarring plays a major role in the pathology, including heart, kidney, liver, and lung disease.

NIO Building New EV and Battery Factory for 2022

NIO is starting to build its second electric car and battery factory in the Neo Park in Hefei, with production scheduled for the third quarter of 2022, William Li, founder, chairman and CEO of NIO. Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million...

The pandemic has roiled surrogacy. What’s an ethical path going forward?

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation. [T]he pandemic has created new challenges to engaging in international surrogacy ethically due to changes in how healthcare is administered, limiting face-to-face interactions, and of course, increasing the health risks for everyone involved – women and other people acting as surrogates and egg donors, genetic intended parents undergoing medical procedures, and babies born through surrogacy.

FDA Action Alert: Blueprint, Orphazyme and Eton

The month of June continues to be busy for the U.S. Food and Drug Administration (FDA). There are three PDUFA dates on the calendar for this week. Here’s a look. Blueprint Medicines’ Avapritinib for Advanced Systemic Mastocytosis. Blueprint Medicines has a target action date of June 16, 2021, for its...
StocksPosted by
The Motley Fool

After a 50% Gain, Is It Too Late to Buy Biogen?

Biogen (NASDAQ:BIIB) investors cheered earlier this week after the biotech company scored a major regulatory victory. The U.S. Food and Drug Administration approved its controversial Alzheimer's drug. As a result, the shares soared nearly 50% in one trading session. Now, some investors are wondering whether it's too late to get...
IndustryPosted by
The Motley Fool

How Big Is Bristol Myers Squibb's Latest FDA Approval?

Bristol Myers Squibb (NYSE:BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis. In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli discuss just how big this FDA win is for Bristol Myers Squibb.

Moderna Inks Partnership Deal with Tabuk Pharmaceuticals

The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session. The financial terms of the deal have not been disclosed. Per the agreement,...

Cantor Fitzgerald Trims Vertex Pharmaceuticals (NASDAQ:VRTX) Target Price to $281.00

Several other research analysts also recently commented on VRTX. Robert W. Baird lowered their target price on Vertex Pharmaceuticals from $252.00 to $240.00 and set an outperform rating for the company in a research note on Friday. They noted that the move was a valuation call. Royal Bank of Canada reduced their price target on Vertex Pharmaceuticals from $262.00 to $242.00 and set an outperform rating on the stock in a report on Friday. Morgan Stanley reduced their price target on Vertex Pharmaceuticals from $254.00 to $205.00 and set an equal weight rating on the stock in a report on Friday. Zacks Investment Research upgraded Vertex Pharmaceuticals from a sell rating to a hold rating and set a $226.00 price target on the stock in a report on Wednesday, May 5th. Finally, Daiwa Capital Markets cut Vertex Pharmaceuticals from an outperform rating to a neutral rating and set a $210.00 price target on the stock. in a report on Friday. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Vertex Pharmaceuticals presently has a consensus rating of Buy and an average price target of $276.10.

A Meme Stock Is Born: How to Spot the Next Reddit Favorite

(Bloomberg) — Trying to sustain with the frenzied rise of so-called meme shares may really feel a bit like taking part in a sport of whack-a-mole, bewildering analysts and buyers alike. While there’s no steadfast definition of what constitutes a meme inventory, one frequent thread throughout the many names being...

3 Monster Growth Stocks That Could Reach New Highs

Let’s discuss development shares. These are shares which have proven robust and sustained share worth appreciation, generally ranging into triple-digit positive aspects over the course of a yr or extra. In brief, these are shares that make traders say, “If only I’d bought in when…!”. There’s no level dwelling on...

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis (CF) therapy, ETD001. The first-in-man safety study is being conducted in healthy participants. ETD001 is an ENaC ion channel inhibitor with best-in-class potential aimed at treating all people with CF.
BusinessPosted by
The Motley Fool

Chamath Palihapitiya's 4 New SPACs Are Getting Ready to Launch

Chamath Palihapitiya has certainly made a name for himself in the world of special purpose acquisition companies, having facilitated the public debuts of Virgin Galactic Holdings, Opendoor Technologies, Clover Health, and SoFi Technologies. Now, Palihapitiya is getting ready to launch four new blank-check companies, all with specific subsectors of healthcare to target. In this Fool Live video clip, recorded on June 7, Fool contributor Matt Frankel and Industry Focus host Jason Moser discuss what investors need to know about the four upcoming SPACs.